Independent Director · Allogene Therapeutics, Inc. (ALLO)

Franz Humer, Ph.D director compensation at Allogene (FY2025): $275K

Fiscal year 2025 director compensation for Franz Humer, Ph.D at Allogene Therapeutics, Inc.. Every figure below is printed as the company filed it and cited to the filing it came from.

Director compensation as of the proxy filed April 30, 2026 (DEF 14A). Open the filing on EDGAR.

Free

Get Franz Humer, Ph.D’s full pay file as a PDF — free

More than this page: up to 10 years of Franz’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Franz Humer, Ph.D and every company like it: Velarion Intel, free for 3 days, no card →

What they were paid

Allogene Therapeutics Director Compensation Table · all 5 fiscal years held
In US dollars, as Allogene Therapeutics reports it. Most recent year first. Totals are the company’s disclosed totals.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$151,813$123,066$0$0$274,879
FY2024$122,390$149,999$149,325$0$421,714
FY2023$160,000$424,998$0$0$584,998
FY2022$160,000$424,992$0$0$584,992
FY2021$163,125$424,988$0$0$588,113

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Allogene Therapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001628280-26-028948, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Allogene Therapeutics, Inc. filed document, accession 0001628280-26-028948. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.

Get the Allogene Therapeutics Board Governance Report

$274,879 Franz Humer, Ph.D, FY2025 total director compensation

$500

The free page is the headline figures. The board report is director pay, board composition and committee fees combined into the same kind of document.

Data as of April 30, 2026 · Source: Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

How this board is paid

company policy · FY2025

Allogene Therapeutics pays directors a $40,000 cash retainer and $300,000 in RSUs/Options.

The rest of the Allogene Therapeutics board

FY2025 · as the company reported each
DirectorRoleFY2025 total
Arie Belldegrun, M.DChair of the Board$4,077,520
David BondermanIndependent Director$0
David Chang, M.D., Ph.DDirector—
Deborah MessemerIndependent Director$193,066
Elizabeth BarrettIndependent Director$183,066
John DeYoungIndependent Director$0
Joshua KazamDirector$170,066
Owen Witte, M.DIndependent Director$193,066
Stephen Mayo, Ph.DIndependent Director$181,642
Todd SisitskyIndependent Director$0
Vicki Sato, Ph.DIndependent Director$182,224

The full Allogene Therapeutics compensation record

free company brief

This page is one director within Allogene Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.

Peer companies

named in the Allogene Therapeutics proxy · each links to its own free brief

Order ALLO

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Board Governance Report